AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04129710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
Study NCT04129710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
Study NCT04129710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
Study NCT04129710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
Study NCT04129710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 conventional infusion on day 1
Study NCT04129710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 conventional infusion on day 1
Study NCT04129710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 250 mg/m2 over 3 hours on day3
Study NCT01183728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cells (MSV)
Description: Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
Study NCT01567254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guided imaginary
Description: Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.
Study NCT01567254 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: music ONLY
Description: music. It will be equal in length to the auditory guided imagery disk
Study NCT03293706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHO Control 1 and 2 Glucose
Description: mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
Study NCT03293706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 1 Slowly Digested
Description: mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
Study NCT03293706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 2 Digestion Resistant
Description: mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
Study NCT03293706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 3 Low Sugar
Description: mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
Study NCT03293706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 4 Maltodextrin
Description: mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
Study NCT01816516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Babies
Description: Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).~The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects.
Study NCT01816516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expanded Food and Nutrition Education Program
Description: Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
Study NCT00461851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
Study NCT00461851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given on day 1 to an AUC of 5.
Study NCT00461851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
Study NCT04018391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped care for nonadherence and depression
Description: * Problem Solving for Depression and Adherence: A 6-session adherence and depression intervention based on a culturally adapted LifeSteps and Problem Solving Therapy for Depression.~* Stepped Care Assessment for Antidepressant Treatment: If a participant's depression score remains above threshold in Session 6, the study interventionist will refer the participant to a Research Mental Health Nurse for a psychopharmacological assessment to prescribe an antidepressant to augment Problem Solving for Depression and Adherence.
Study NCT04018391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced Usual Care: A combination of 1) clinic-provided adherence counseling, 2) access to providers trained in the World Health Organization Mental Health Gap Intervention Guide (mhGAP), 3) a letter to the participant's medical provider detailing the depression diagnosis, 4) access to the treatment components of the TENDAI intervention at no cost, after the participant has completed their 12-month follow-up assessment.
Study NCT00365872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell (DC) Injections
Description: * DCs (10\^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.~* One additional DC injection was given before surgery to assess DC migration~* Patients were assigned to one of three cohorts:~Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery
Study NCT00365872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation was delivered 5 days per week (Monday-Friday).
Study NCT00365872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete Resection - Surgery for tumor removal
Description: Tumors were surgically resected 3-6 weeks after the completion of EBRT.
Study NCT01602627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 inhibitor AUY922
Description: Given IV
Study NCT01602627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01602627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03998345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 609A
Description: 609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
Study NCT00303290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg Interferon Alpha 2b (Peg Intron)
Description: 4.5 micrograms/kg once a week
Study NCT00303290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C (cytosine arabinoside)
Description: 10 mg under the skin daily
Study NCT01090167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
Study NCT01226602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6140
Description: P2Y12 receptor antagonist
Study NCT01226602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00483431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00483431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MK7
Study NCT01711931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of everolimus-eluting bioresorbable vascular scaffold stent
Study NCT01711931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of everolimus-eluting stents
Study NCT01711931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of biolimus-eluting stents
Study NCT00669240 — intervention group
Intervention type: DRUG
Intervention: Varenicline
Description: According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
Study NCT04087551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Developing the list of items for BRFES
Description: The finalized list of items will be discussed by two researchers who will combine similar items generated by the two focus groups to complete the Balance Recovery Falls-Efficacy Scale. The list of items has been developed by a group of community-dwelling older adults who had demonstrated an understanding of near-falls and will be able to articulate the use of balance recovery strategies used in near-fall experiences.
Study NCT00003389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: given IV
Study NCT00003389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: given IV
Study NCT00003389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: given IV
Study NCT00003389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: given IV
Study NCT00003389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: given IV
Study NCT00003389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: given IV
Study NCT00003389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: given IV
Study NCT00003389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: given IV
Study NCT00003389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechlorethamine
Description: given IV
Study NCT00003389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: given IV
Study NCT00003389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: taken orally
Study NCT00003389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: given IV
Study NCT00003389 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT03441633 — intervention group
Intervention type: DRUG
Intervention: apixaban
Description: current or new medication
Study NCT03441633 — intervention group
Intervention type: DRUG
Intervention: dabigatran
Description: current or new medication
Study NCT03441633 — intervention group
Intervention type: DRUG
Intervention: VKA
Description: current or new medication
Study NCT03441633 — intervention group
Intervention type: DRUG
Intervention: rivaroxaban
Description: current or new medication
Study NCT02003131 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Trophic factors from umbilical cord mesenchymal stem cells
Study NCT03762148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate
Study NCT03762148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous sulphate
Description: nutritional iron (14 mg) supplement in form of ferrous sulphate
Study NCT03762148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferric pyrophosphate
Description: nutritional iron (14 mg) supplement in form of ferric pyrophosphate
Study NCT03762148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + 3.5 g GOS
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (3.5 g GOS)
Study NCT03762148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + 7 g GOS
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS)
Study NCT03762148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous sulphate + 15 g GOS
Description: nutritional iron (14 mg) supplement in form of ferrous sulphate with addition of prebiotics (15 g GOS)
Study NCT03762148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + Vitamin C
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of Vitamin C
Study NCT03762148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferric pyrophosphate + 15 g GOS
Description: nutritional iron (14 mg) supplement in form of ferric pyrophosphate with addition of prebiotics (15 g GOS)
Study NCT03762148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + 7 g GOS + Vitamin C
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS) and Vitamin C
Study NCT03994692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK eminoplasty
Description: making obstacle at eminence using patient specefic PEEK device
Study NCT02843100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Partial Enteral Nutrition
Description: 25-50% of Energy from formula
Study NCT02843100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exclusive Enteral Nutrition
Description: 8 weeks of Exclusive Enteral Nutrition
Study NCT03434600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxford UKA vs Sigma UKA
Study NCT03434600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxford UKA vs Sigma UKA
Study NCT03994692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autogenous onlay grafting eminoplasty
Description: making obstacle at eminence using chin graft
Study NCT01909596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral customized foot orthoses
Description: Foot orthoses with arch support and without lateral inclination
Study NCT01909596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6° lateral customized foot orthoses
Description: Foot orthoses with arch support above insoles with lateral inclination set at 6°
Study NCT01909596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10° lateral customized foot orthoses
Description: Foot orthoses with arch support above insoles with lateral inclination set at 10°
Study NCT00451321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: Infusion
Study NCT03559946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous tibial nerve stimulation (PTNS)
Description: The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
Study NCT03559946 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: percutaneous tibial nerve stimulation (PTNS)
Description: The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
Study NCT03559946 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
Study NCT02064166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Insulin
Description: 1. treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;~2. placebo arm: normal saline, daily, intranasally, for 4 weeks.
Study NCT02064166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Insulin
Description: 1. treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;~2. placebo arm: normal saline, daily, intranasally, for 4 weeks.
Study NCT02083731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Study NCT01424254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule GIVEN IMAGING
Description: Injection of Capsule Endoscopy
Study NCT01424254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Push-Enteroscopy
Description: currently recommended standard
Study NCT01627821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jarvik 2000 VAS
Description: Jarvik 2000 LVAD
Study NCT01627821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMate II
Description: HeartMate II LVAD
Study NCT02167607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Purple Potato
Study NCT02167607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Comparator
Study NCT02208856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS
Study NCT02208856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02208856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat standardized breakfast
Study NCT02662127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIGVARIS® Class 2 - RAL: 23-32.
Description: Below knee graduated elastic compression stocking
Study NCT05451147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chhinnavahni Kashaya Vati along with Agnimantha Kwatha
Description: Drug: Chhinnavahni Kashaya Vati Form : Tablet Dose: 1g TDS (2x500 mg), Before meals Mode of Administration: Oral Anupaan: 20 ml of Agnimantha Kwatha Duration: 3 Months
Study NCT05451147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Drug: Metformin Form: Tablet Dose: 500mg BID/TDS, Before meals Mode of Administration: Oral Anupaan: Plain water Duration: 3 Months
Study NCT01661192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAT( Alpha 1 Antitrypsin)
Study NCT03192592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body moisturizer
Description: Daily body moisturizer application for skin protection and barrier.
Study NCT04147455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted RealConsent
Description: The program is a novel, theory-driven, evidence-based serial drama and educational program tailored to young men and delivered in six episodes via the web. Participants will view six 30-minute modules designed to prevent sexual violence in young men
Study NCT04147455 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control Condition
Description: Participants will view six 30-minute web-based serial drama modules designed to promote health.